A critical reappraisal of current staging of Lewy-related pathology in human brain

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Acta Neuropathologica

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00401-008-0406-yPMID 18592254
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.

  2010cited by this paper
• 4: Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RK. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of alpha-synuclein staging. Neuropathol Appl Neurobiol. 2008

  2009cited by this paper
• CHANGING CONCEPTS IN PARKINSON DISEASE: MOVING BEYOND THE DECADE OF THE BRAIN

  2009cited by this paper
• The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease

  2008cited by this paper
• The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease.

  2008cited by this paper
• Clinicopathological Outline of Dementia with Lewy Bodies Applying the Revised Criteria: The Hisayama Study

  2008cited by this paper
• alpha-Synuclein pathology in the neostriatum in Parkinson's disease.

  2008cited by this paper
• Invited Article: Nervous system pathology in sporadic Parkinson disease

  2008cited by this paper
• Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease

  2008cited by this paper
• Inter-laboratory comparison of neuropathological assessments of β-amyloid protein: a study of the BrainNet Europe consortium

  2008cited by this paper
• α-Synuclein pathology in the neostriatum in Parkinson’s disease

  2008cited by this paper
• Striatal &bgr;-Amyloid Deposition in Parkinson Disease With Dementia

  2008cited by this paper
• Animal models of Parkinson’s disease progression

  2008cited by this paper
• A critical evaluation of the Braak staging scheme for Parkinson's disease

  2008cited by this paper
• Assessment of &agr;-Synuclein Pathology: A Study of the BrainNet Europe Consortium

  2008cited by this paper
• Reduced striatal tyrosine hydroxylase in incidental Lewy body disease

  2008cited by this paper
• Controversies over the staging of α-synuclein pathology in Parkinson’s disease

  2008influential reference
• Morphometry of the human substantia nigra in ageing and Parkinson’s disease

  2008cited by this paper
• Protein misfolding and neurodegeneration.

  2008cited by this paper
• The progression of pathology in longitudinally followed patients with Parkinson’s disease

  2008cited by this paper
• Striatal β-Amyloid Deposition in Parkinson Disease With Dementia. Authors' reply

  2008cited by this paper
• Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance

  2008cited by this paper
• New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central?

  2008cited by this paper
• Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease

  2008cited by this paper
• The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α‐synuclein staging

  2008influential reference
• Is REM sleep Behaviour Disorder (RBD) a risk factor of dementia in idiopathic Parkinson's disease?

  2008cited by this paper
• Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

  2008influential reference
• Striatal beta-amyloid deposition in Parkinson disease with dementia.

  2008cited by this paper
• Systematic Appraisal Using Immunohistochemistry of Brain Pathology in Aged and Demented Subjects

  2008cited by this paper
• BEATING A DEAD HORSE: DOPAMINE AND PARKINSON DISEASE

  2008cited by this paper
• Co-localization of tau and α-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies

  2008cited by this paper
• The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years

  2008cited by this paper
• A not entirely benign procedure: progression of Parkinson’s disease

  2008cited by this paper
• Emergence of Parkinson's disease in essential tremor: A study of the clinical correlates in 53 patients

  2008cited by this paper
• Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

  2008cited by this paper
• Invited Article: Changing concepts in Parkinson disease

  2008cited by this paper
• A Modern Hypothesis: The Distinct Pathologies of Dementia Associated with Parkinson’s Disease versus Alzheimer’s Disease

  2008cited by this paper
• Cortical α-synuclein load is associated with amyloid-β plaque burden in a subset of Parkinson’s disease patients

  2008cited by this paper
• Patterns and stages of α-synucleinopathy

  2008cited by this paper
• Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

  2007cited by this paper
• Classical Parkinson disease versus Parkinson complex – Reflections against staging and in favour of heterogeneity

  2007cited by this paper
• Amyloid Deposition Begins in the Striatum of Presenilin-1 Mutation Carriers from Two Unrelated Pedigrees

  2007cited by this paper
• The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α‐synuclein aggregates

  2007cited by this paper
• The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part II

  2007cited by this paper
• Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?—A [99mTc]‐TRODAT‐1 SPECT study

  2007cited by this paper
• Morphological substrates of parkinsonism with and without dementia: a retrospective clinico-pathological study.

  2007cited by this paper
• The Etiopathogenesis of Parkinson Disease and Suggestions for Future Research. Part I

  2007cited by this paper
• In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution

  2007cited by this paper
• Bowel movement frequency in late‐life and incidental Lewy bodies

  2007cited by this paper
• Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs.

  2007cited by this paper
• Parkinson's disease: a dual‐hit hypothesis

  2007cited by this paper
• Research into neurodegenerative disease: an entangled web of mice and men

  2007cited by this paper
• Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease.

  2007cited by this paper
• THE PROGRESSION OF PARKINSON DISEASE: A HYPOTHESIS

  2007cited by this paper
• DLB and PDD boundary issues

  2007cited by this paper
• Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease.

  2007cited by this paper
• The progression of Parkinson disease

  2007cited by this paper
• Presynaptic α-Synuclein Aggregates, Not Lewy Bodies, Cause Neurodegeneration in Dementia with Lewy Bodies

  2007cited by this paper
• 10 – Protein Aggregation Disorders

  2007cited by this paper
• Lewy body variant of Alzheimer’s disease or cerebral type Lewy body disease? Two autopsy cases of presenile onset with minimal involvement of the brainstem

  2007cited by this paper
• Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.

  2007cited by this paper
• Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons

  2007cited by this paper
• Relating mode of action to clinical practice: dopaminergic agents in Parkinson's disease.

  2007cited by this paper
• Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study

  2007cited by this paper
• Lewy Body Disorders

  2007influential reference
• Alpha‐Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism

  2006cited by this paper
• Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies

  2006cited by this paper
• Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

  2006cited by this paper
• Subjective complaints precede Parkinson disease: the rotterdam study.

  2006cited by this paper
• Atypical protein kinase C in neurodegenerative disease II: PKCiota/lambda in tauopathies and alpha-synucleinopathies.

  2006cited by this paper
• Parkinson's disease: premotor clinico-pathological correlations.

  2006cited by this paper
• Interaction between Aβ Peptide and α Synuclein: Molecular Mechanisms in Overlapping Pathology of Alzheimer’s and Parkinson’s in Dementia with Lewy Body Disease

  2006cited by this paper
• Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson's disease.

  2006cited by this paper
• Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra.

  2006cited by this paper
• Etiology of Parkinson’s disease

  2006cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop

  2006cited by this paper
• Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis

  2006cited by this paper
• Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals.

  2006cited by this paper
• Pathology associated with sporadic Parkinson's disease--where does it end?

  2006influential reference
• Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs

  2006cited by this paper
• Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?

  2006cited by this paper
• New developments of brain imaging for Parkinson's disease and related disorders

  2006cited by this paper
• Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.

  2006cited by this paper
• Interface between tauopathies and synucleinopathies: A tale of two proteins

  2006cited by this paper
• Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.

  2006cited by this paper
• Atypical Protein Kinase C in Neurodegenerative Disease II: PKC&igr;/&lgr; in Tauopathies and &agr;-Synucleinopathies

  2006cited by this paper
• α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects

  2006cited by this paper
• Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy

  2006influential reference
• Progression patterns of neuronal loss and Lewy body pathology in the substantia nigra in Parkinson's disease

  2006cited by this paper
• Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease.

  2006cited by this paper
• Biochemical and pathological characterization of Lrrk2

  2006cited by this paper
• Predicting Parkinson’s disease: worthwhile but are we there yet?

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.

  2005cited by this paper
• Profound Cardiac Sympathetic Denervation Occurs in Parkinson Disease

  2005cited by this paper
• Aβ deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases

  2005cited by this paper
• Dementia with Lewy bodies and Parkinson's disease with dementia: are they different?

  2005cited by this paper
• Pathological substrate of dementia in Parkinson's disease--its relation to DLB and DLBD.

  2005cited by this paper
• α‐Synuclein pathology does not predict extrapyramidal symptoms or dementia

  2005cited by this paper
• Staging of Sporadic Parkinson Disease-Related α-Synuclein Pathology: Inter- and Intra-Rater Reliability

  2005cited by this paper

• A Pathophysiological Model of Parkinson's Disease Based on Microvascular Flow Disturbance and Leukocyte-Mediated Oxidative Injury in Critical Pigmented Neuronal Niches.

  2026cites this paper
• Microvascular and Macrovascular Cerebral Disease Profiles and Their Association With Cognitive Abilities: A Cross-Sectional Clinical Pathological Study.

  2026cites this paper
• Large-scale visualization of α-synuclein oligomers in Parkinson's disease brain tissue.

  2025cites this paper
• Vers un traitement neuroprotecteur dans la maladie de Parkinson ? La « cible alphasynucléine »

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Evaluation of cerebrospinal fluid levels of VAMP-2 and SNAP-25 in a dementia with Lewy bodies clinical cohort stratified by Alzheimer’s pathophysiological biomarkers

  2025cites this paper
• α-Synuclein pathology and mitochondrial dysfunction: Toxic partners in Parkinson's disease.

  2025cites this paper
• Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue

  2024cites this paper
• Molecular and cellular mechanisms of selective vulnerability in neurodegenerative diseases

  2024cites this paper
• Current concepts and molecular pathology of neurodegenerative diseases.

  2024cites this paper
• The Association Between Neuropathological Lesions and Body Mass Index Is Independent of Cognitive Abilities

  2024cites this paper
• Early detection of diseases causing dementia using digital navigation and gait measures: A systematic review of evidence

  2024cites this paper
• Neuronal threshold functions: Determining symptom onset in neurological disorders

  2024cites this paper
• THE HABENULA IN PARKINSON'S DISEASE: ANATOMY, FUNCTION, AND IMPLICATIONS FOR MOOD DISORDERS - A NARRATIVE REVIEW.

  2024cites this paper
• Synucleinopathies.

  2023cites this paper
• Targeting the Cysteine Redox Proteome in Parkinson’s Disease: The Role of Glutathione Precursors and Beyond

  2023cites this paper
• Association between APOE-ε4 allele and cognitive function is mediated by Alzheimer’s disease pathology: a population-based autopsy study in an admixed sample

  2023cites this paper
• Rehabilitation for non-motor symptoms for patients with Parkinson's disease from an α-synuclein perspective: a narrative review.

  2023cites this paper
• Presence but not the timing of onset of REM sleep behavior disorder distinguishes evolution patterns in Parkinson's disease.

  2023cites this paper
• Pre-clinical Aspects and Contemporary Treatments of Parkinson's Disease.

  2023cites this paper
• Neuropathology of incidental Lewy body & prodromal Parkinson’s disease

  2023cites this paper
• Dystonia and Parkinson's disease: Do they have a shared biology?

  2023cites this paper
• A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer’s Disease and Lewy Body Dementia

  2023cites this paper
• α-Synuclein in synaptic function and dysfunction.

  2022cites this paper
• Discrepancy between distribution of alpha-synuclein oligomers and Lewy-related pathology in Parkinson’s disease

  2022cites this paper
• Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson’s disease

  2022cites this paper
• Regional Selectivity of Neuromelanin Changes in the Substantia Nigra in Atypical Parkinsonism

  2022cites this paper
• N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases

  2022cites this paper
• Neuropathological substrates of cognition in Parkinson's disease.

  2022cites this paper
• Morphological basis of Parkinson disease-associated cognitive impairment: an update

  2022cites this paper
• Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota

  2021cites this paper
• Expression Levels of an Alpha-Synuclein Transcript in Blood May Distinguish between Early Dementia with Lewy Bodies and Parkinson’s Disease

  2021cites this paper
• Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis

  2021cites this paper
• Transcutaneous vagus nerve stimulation (tVNS) as a potential therapeutic application for neurodegenerative disorders - A focus on dysautonomia in Parkinson's disease.

  2021cites this paper
• Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?

  2021cites this paper
• Parkinson's disease

  2021cites this paper
• The Association Between REM Sleep Behavior Disorder and Autonomic Dysfunction in Parkinson’s Disease

  2021cites this paper
• The Scientific and Lay Narratives

  2020cites this paper
• The Hypothesis That Refuses to Die

  2020cites this paper
• Disease “Redefinition”: A Tough Pill to Swallow

  2020cites this paper
• Our Living Dissonance

  2020cites this paper
• Index

  2020cites this paper
• Protein Paradox

  2020cites this paper
• Biomarkers: The Promise and the Fallacy

  2020cites this paper
• Note Added at Press Time – Reviving LOF

  2020cites this paper
• Proteomic complexity in parkinson's disease: a redox signaling perspective of the pathophysiology and progression.

  2020cites this paper
• Olfactory disturbances in Parkinson’s disease

  2020cites this paper
• Symptomatic vs. Disease-Modifying Therapies

  2020cites this paper
• The Fault in Our Models

  2020cites this paper
• Pieces of a Puzzle?

  2020cites this paper
• L‐DOPA regulates α‐synuclein accumulation in experimental parkinsonism

  2020cites this paper
• Bifluorescent Analysis of ⍺-Synuclein Aggregation In Vivo

  2020cites this paper
• Preface 2 – Enter Patient

  2020cites this paper
• Dementia With Lewy Bodies

  2020cites this paper
• Brain Fables

  2020cites this paper
• Predictions for the 2020s and Beyond

  2020cites this paper
• Genetics of Parkinson's disease.

  2020cites this paper
• The Shaky Six and the “Second Reality”

  2020cites this paper
• Lessons from Oncology

  2020cites this paper
• Disease Subtypes: The Promise and the Fallacy

  2020cites this paper
• The Moonshot: Population-Based Studies of Aging

  2020cites this paper
• Epilogue

  2020cites this paper
• Challenges Viewed from Afar

  2020cites this paper
• Preface 1 – The Question

  2020cites this paper
• Parkinson Disease Propagation Using MRI Biomarkers and Partial Least Squares Path Modeling

  2020influential citation
• References

  2020cites this paper
• Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

  2019cites this paper
• Mass synaptometry: High-dimensional multi parametric assay for single synapses.

  2019cites this paper
• Neocortical Lewy bodies are associated with impaired odor identification in community-dwelling elders without clinical PD

  2019cites this paper
• Contribution of cholinergic innervation to adult hippocampal neurogenesis in dementia

  2019cites this paper
• Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

  2019cites this paper
• Striatal dopamine activity and myocardial 123I-metaiodobenzylguanidine uptake in early Parkinson's disease.

  2019cites this paper
• Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease

  2019cites this paper
• Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities

  2019cites this paper
• Molecular pathology of neurodegenerative diseases: principles and practice

  2019cites this paper
• Recent Developments in LRRK 2 ‐ Targeted Therapy for Parkinson ’ s Disease

  2019cites this paper
• Gray matter correlates of progression of motor symptoms in patients with Parkinson’s disease

  2019cites this paper
• Pathophysiological mechanisms of non-motor features and their role on the pathogenic process in Parkinson's disease

  2019cites this paper
• Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease

  2019cites this paper
• Recent Developments in LRRK2-Targeted Therapy for Parkinson’s Disease

  2019cites this paper
• Unique α-synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression

  2019cites this paper
• The center of olfactory bulb‐seeded α‐synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice

  2019cites this paper
• Typage moléculaire des maladies neurodégénératives dues à l’agrégation de la protéine alpha synucléine

  2019influential citation
• Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling.

  2019influential citation
• The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

  2018cites this paper
• Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy

  2018cites this paper
• Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD?

  2018cites this paper
• Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease

  2018cites this paper
• Imaging Parkinsonian Pathology in Substantia Nigra with MRI

  2018cites this paper
• Living with Lewy body dementia. Treatment, survival & quality of life.

  2018cites this paper
• Les synucléinopathies sont-elles des maladies à prions ?

  2018cites this paper
• Alternative Splicing of Alpha- and Beta-Synuclein Genes Plays Differential Roles in Synucleinopathies

  2018cites this paper
• Neuropathological diagnoses and clinical correlates in older adults in Brazil: A cross-sectional study

  2017cites this paper
• The Threshold Theory for Parkinson's Disease.

  2017cites this paper
• Are exosomes the vehicle for protein aggregate propagation in neurodegenerative diseases?

  2017cites this paper
• Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations.

  2017cites this paper
• Evaluation of the Braak staging of brain pathology with 1H-MRS in patients with Parkinson's disease.

  2017cites this paper
• An order in Lewy body disorders: Retrograde degeneration in hyperbranching axons as a fundamental structural template accounting for focal/multifocal Lewy body disease

  2017cites this paper
• Cerebrovascular Lesions in Mixed Neurodegenerative Dementia: A Neuropathological and Magnetic Resonance Study

  2017cites this paper
• Exploring Braak’s Hypothesis of Parkinson’s Disease

  2017cites this paper